Department of Plastic Surgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Int J Mol Sci. 2021 Oct 14;22(20):11104. doi: 10.3390/ijms222011104.
Vascularized composite allografts contain various tissue components and possess relative antigenicity, eliciting different degrees of alloimmune responses. To investigate the strategies for achieving facial allograft tolerance, we established a mouse hemiface transplant model, including the skin, muscle, mandible, mucosa, and vessels. However, the immunomodulatory effects of the mandible on facial allografts remain unclear. To understand the effects of the mandible on facial allograft survival, we compared the diversities of different facial allograft-elicited alloimmunity between a facial osteomyocutaneous allograft (OMC), including skin, muscle, oral mucosa, and vessels, and especially the mandible, and a myocutaneous allograft (MC) including the skin, muscle, oral mucosa, and vessels, but not the mandible. The different facial allografts of a BALB/c donor were transplanted into a heterotopic neck defect on fully major histocompatibility complex-mismatched C57BL/6 mice. The allogeneic OMC (Allo-OMC) group exhibited significant prolongation of facial allograft survival compared to the allogeneic MC group, both in the presence and absence of FK506 immunosuppressive drugs. With the use of FK506 monotherapy (2 mg/kg) for 21 days, the allo-OMC group, including the mandible, showed prolongation of facial allograft survival of up to 65 days, whereas the myocutaneous allograft, without the mandible, only survived for 34 days. The Allo-OMC group also displayed decreased lymphocyte infiltration into the facial allograft. Both groups showed similar percentages of B cells, T cells, natural killer cells, macrophages, and dendritic cells in the blood, spleen, and lymph nodes. However, a decrease in pro-inflammatory T helper 1 cells and an increase in anti-inflammatory regulatory T cells were observed in the blood and lymph nodes of the Allo-OMC group. Significantly increased percentages of donor immune cells were also observed in three lymphoid organs of the Allo-OMC group, suggesting mixed chimerism induction. These results indicated that the mandible has the potential to induce anti-inflammatory effects and mixed chimerism for prolonging facial allograft survival. The immunomodulatory understanding of the mandible could contribute to reducing the use of immunosuppressive regimens in clinical face allotransplantation including the mandible.
血管化复合组织同种异体移植物包含各种组织成分,并具有相对的抗原性,引发不同程度的同种免疫反应。为了研究实现面部同种异体移植物耐受的策略,我们建立了一种小鼠半面移植模型,包括皮肤、肌肉、下颌骨、黏膜和血管。然而,下颌骨对面部同种异体移植物的免疫调节作用尚不清楚。为了了解下颌骨对面部同种异体移植物存活的影响,我们比较了包括皮肤、肌肉、口腔黏膜和血管以及下颌骨在内的面部骨-肌-皮复合组织同种异体移植物(OMC)和不包括下颌骨的单纯皮-肌-黏膜复合组织同种异体移植物(MC)对面部同种异体移植物诱导的同种免疫的多样性。BALB/c 供体的不同面部同种异体移植物被移植到完全主要组织相容性复合物错配的 C57BL/6 小鼠的异位颈部缺损中。与单纯皮-肌-黏膜复合组织同种异体移植物组相比,无论是否使用 FK506 免疫抑制剂,同种异体 OMC(Allo-OMC)组的面部同种异体移植物存活时间明显延长。使用 FK506 单药治疗(2mg/kg)21 天,包括下颌骨的 allo-OMC 组的面部同种异体移植物存活时间延长至 65 天,而不包括下颌骨的单纯皮-肌-黏膜复合组织同种异体移植物仅存活 34 天。allo-OMC 组还显示出面部同种异体移植物中淋巴细胞浸润减少。两组在血液、脾脏和淋巴结中的 B 细胞、T 细胞、自然杀伤细胞、巨噬细胞和树突状细胞百分比相似。然而,在 allo-OMC 组的血液和淋巴结中观察到促炎 Th1 细胞减少和抗炎调节性 T 细胞增加。在 allo-OMC 组的三个淋巴器官中也观察到供体免疫细胞的百分比显著增加,提示混合嵌合体的诱导。这些结果表明,下颌骨具有诱导抗炎作用和混合嵌合体以延长面部同种异体移植物存活的潜力。对下颌骨的免疫调节理解有助于减少包括下颌骨在内的临床面部同种异体移植中免疫抑制剂方案的使用。